Conference Coverage

ESC: Alirocumab ‘cures’ heterozygous familial hypercholesterolemia

Publish date: September 15, 2015

 

AT THE ESC CONGRESS 2015

References

The HeFH studies were supported by Sanofi and Regeneron Pharmaceuticals. Dr. Kastelein reported having received consulting fees from those pharmaceutical companies and nearly two dozen others.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

ACC/AHA cholesterol guideline found efficient, cost effective
MDedge Cardiology
FDA approves alirocumab, first injectable lipid-lowering biologic therapy
MDedge Cardiology
Adding ezetimibe to atorvastatin boosts coronary plaque regression
MDedge Cardiology
Study links statin use to lower mortality in RA patients
MDedge Cardiology
Testosterone therapy didn’t boost atherosclerosis over 3 years
MDedge Cardiology
Mobile health technology may encourage behavioral change
MDedge Cardiology
Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients
MDedge Cardiology
FDA warns of disabling joint pain from DPP-4 inhibitors
MDedge Cardiology
ESC: MI survival of 40-somethings has improved dramatically
MDedge Cardiology
ESC: Statins reduce postoperative noncardiac surgery event rates
MDedge Cardiology

Related Articles